Kolon Group reduces financial risk from Invossa gene therapy as legal challenges ease, boosting corporate value with the drug’s U.S. market potential nearing $7.5 billion.
#YonhapInfomax #KolonGroup #Invossa #LegalRisks #TGC #FDAApproval #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=104258
Kolon Eases Financial Burden from Invossa Development as Legal Hurdles Gradually Clear
Kolon Group reduces financial risk from Invossa gene therapy as legal challenges ease, boosting corporate value with the drug’s U.S. market potential nearing $7.5 billion.
Kolon Group Adopts 'AI+Excellence' as New Year's Message—AI as One Team
Kolon Group launches 'AXcellence 2026,' integrating AI and excellence to drive innovation and growth, positioning AI as a core team member for future value creation.
Kolon Group Vice Chairman Lee Kyu-ho has purchased affiliate shares for the first time, signaling a commitment to responsible management and group reform as Kolon returns to profitability and its stock surges 281% year-to-date.
#YonhapInfomax #KolonGroup #LeeKyuHo #SharePurchase #OperatingProfit #CorporateReform #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=93605
Yonhap Infomax News